Podcast Summary: How I Invest with David Weisburd Episode: E193: GLP-1s, AI & the End of Sick Care: The Next $10B Health Tech Giant
Release Date: July 30, 2025

Introduction to Maximus and Performance Medicine

Timestamp [00:00 - 01:32]

The episode kicks off with Speaker B introducing Maximus, a consumer healthcare technology startup founded in 2020. Maximus is positioned as an online clinic revolutionizing performance medicine, shifting the focus from the traditional "sick care" system to proactive health and optimization.

Key Points:

• Performance Medicine vs. Sick Care: While the existing healthcare system excels in treating illnesses, it falls short in preventing diseases and enhancing overall health and longevity.
• Target Audience: Maximus caters not only to those with medical conditions but also to healthy individuals seeking to optimize their physical and mental performance.

Notable Quote:

"Performance medicine is really a new paradigm shift... protocols that we provide are not just for people who have an illness but for people who can be completely healthy and want to look, feel, or perform their best." – Speaker B [00:01:10]

Lessons from Omada and Emphasis on Scientific Validation

Timestamp [01:32 - 07:58]

Speaker A discloses investment in Speaker B based on their successful involvement with Omada, a billion-dollar public company. Speaker B shares invaluable lessons from Omada that are applied to Maximus.

Key Points:

• Scientific Backing: At Omada, emphasis was placed on establishing the company as science-based, conducting rigorous clinical trials to validate their programs.
• Publication and Transparency: Published multiple research papers demonstrating the efficacy of their online weight loss programs, setting a foundation of trust and credibility.
• Contrast with Competitors: Unlike many telemedicine companies that do not publish research, Maximus prioritizes scientific validation to ensure effectiveness and safety.

Notable Quote:

"We hold ourselves to the highest gold standard of running clinical trials to prove that what we do works." – Speaker B [01:49]

Maximus’s Approach to Drug Development and Clinical Trials

Timestamp [05:58 - 07:40]

Speaker A probes into how Maximus manages to publish research without massive funding, leading Speaker B to elaborate on their strategic approach.

Key Points:

• Utilizing Existing FDA Approvals: Maximus leverages already approved drugs, modifying delivery systems and dosages tailored to healthier populations, thereby avoiding expensive multi-stage FDA trials.
• Lean Research Methodology: By focusing on known compounds and optimizing their usage, Maximus conducts efficient and cost-effective trials.
• Ensuring Efficacy and Safety: Emphasizes the importance of data-driven approaches to confirm the effectiveness of their treatments, distinguishing themselves from companies selling ineffective alternatives like GLP1 gummies.

Notable Quote:

"Maximus actually run clinical trials. You can go to our website, for instance... show me the data." – Speaker B [06:44]

Understanding GLP-1s and Their Growing Popularity

Timestamp [07:40 - 15:15]

Speaker A asks Speaker B to delve deeper into GLP-1s, their purpose, side effects, and the trend of microdosing.

Key Points:

• Function of GLP-1s: Originally prescribed for diabetes, GLP-1s (like Ozempic and Wegovy) help in weight loss by mimicking a natural hormone that increases insulin secretion, decreases appetite, and slows digestion.
• Microdosing Trend: Due to high demand and shortages, compounded lower-dose versions are being used by individuals who are not obese but seek weight loss and other health benefits without severe side effects.
• Broader Applications: Beyond weight loss, users report improved impulse control, reduced inflammation, and better overall metabolic health.

Notable Quote:

"I think GLPs are revolutionary in that people are going to take the just right personalized dose to get to their optimal state." – Speaker B [14:30]

The Future of Obesity Treatment and Population Health

Timestamp [15:15 - 24:14]

The conversation shifts to the broader implications of GLP-1s on public health, with Speaker B predicting widespread adoption and significant shifts in health standards.

Key Points:

• High Prevalence of Metabolic Issues: With 88% of Americans having some metabolic abnormality, the potential market for GLP-1s is vast.
• Sustainability of Weight Loss: Most weight loss treatments, including GLP-1s, require ongoing use to maintain results, similar to how vitamin D supplementation is necessary for optimal health.
• Behavioral Integration: Combining medications with lifestyle interventions enhances effectiveness, helping individuals make sustainable health changes.

Notable Quote:

"The majority of Americans in the next five to 10 years are going to be on GLP1." – Speaker B [16:10]

Addressing Stigma and Changing Societal Perceptions

Timestamp [24:14 - 30:35]

Speaker B discusses the societal shift from stigmatizing medication use to viewing it as a badge of honor and personal optimization.

Key Points:

• Destigmatization of Medications: Just as psychotherapy and personal training have become prestigious, performance-enhancing medications like GLP-1s and testosterone will be embraced as markers of health and personal commitment.
• Convenience of Administration: Innovations in drug delivery, such as oral formulations and subcutaneous injections, are making medications more accessible and less intimidating.
• AI Integration: The role of AI in optimizing dosing, enhancing coaching, and improving patient outcomes is highlighted as a critical component of future healthcare models.

Notable Quote:

"You're on testosterone, not because you particularly need it, it's because you want it and you're better for it." – Speaker B [28:00]

The Role of AI in Healthcare and Maximus

Timestamp [30:35 - 35:48]

Speaker A introduces the topic of AI's impact on healthcare, leading Speaker B to expound on its integration within Maximus.

Key Points:

• Research and Development: AI accelerates the research process, enabling rapid data analysis and publication.
• Clinical Decision Support: AI assists doctors in optimizing dosage and treatment plans based on comprehensive patient data, reducing the iteration cycles needed for effective treatment.
• Enhanced Coaching: AI-powered virtual coaches provide 24/7 support, personalized dietary analysis, and body composition tracking, significantly enhancing patient engagement and outcomes.

Notable Quote:

"AI will supplement and support doctors, not completely replace them." – Speaker B [31:45]

Optimizing Personal Health through Routine Testing

Timestamp [35:48 - 42:57]

The discussion transitions to personal health optimization, with Speaker B emphasizing the importance of routine diagnostic testing.

Key Points:

• Primary Care Importance: Encourages having a primary care physician for foundational health checks, while supplements like Maximus provide specialized performance medicine.
• Routine Blood Tests: Recommends annual or bi-annual blood panels to monitor critical health markers such as blood sugar, testosterone levels, thyroid function, and vitamin D.
• Innovations in Testing: Maximus offers at-home blood testing devices that are less invasive and more convenient, democratizing access to essential health data.

Notable Quote:

"Only 12% of the country is actually perfectly healthy. The majority have some metabolic abnormality." – Speaker B [37:00]

Conclusion and Future Outlook

Timestamp [42:57 - End]

The episode wraps up with Speaker A expressing gratitude for Speaker B’s insights and investment, highlighting the transformation from personal practice to a scalable business model through Maximus.

Key Points:

• Scalability of Performance Medicine: Maximus aims to democratize access to performance-enhancing treatments, making them affordable and accessible to a broader population.
• Vision for Health Optimization: The integration of scientific validation, AI, and innovative delivery systems positions Maximus to be a leader in the next wave of health tech giants.

Notable Quote:

"Maximus essentially, to your point, is a scalable version of that... democratize performance medicine." – Speaker B [43:22]

Final Thoughts

This episode of "How I Invest with David Weisburd" provides a comprehensive overview of Maximus’s innovative approach to performance medicine, the strategic lessons learned from Omada, and the transformative potential of GLP-1s combined with AI technologies. Speaker B’s insights underscore a significant shift in healthcare from reactive sick care to proactive health optimization, positioning Maximus as a pivotal player in this emerging landscape.

For More Information:

• Maximus Website: www.maximushealth.com
• Contact: davidisburgcapital.com

If you enjoyed this summary, please share it with a friend and subscribe to "How I Invest with David Weisburd" for more insightful episodes.